1,721,118 research outputs found
Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes
No full textRetuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant
No full textSeveral findings suggest that the pathogenesis and clinical history of myelodysplastic syndromes (MDS) is influenced by a variety of immune pathways and mechanisms. Coherently several therapeutic approaches based on the idea of modulating the immune system have been exploited in this clinical setting. The present review will first consider more consolidated strategies such as antithymocyte globulin and immunomodulatory (IMiDs) analogues. Less explored approaches, such as anti tumor necrosis factor antibodies, cyclosporin and bortezomib will be also evaluated. Finally the potential impact of anti-tumour vaccination or hemopoietic cell transplantation on the outcome of MDS patients will be addressed
The Role of Clofarabine in the treatment of adults with acute myeloidleukemia
No full textThe therapeutic scenario available for adult patients with acute myeloid leukemia (AML) has shown only partial progresses over the last few years. This is especially true for refractory and relapsed AML whose outcome is still extremely disappointing. In this context Clofarabine has offered new promising perspectives within first and second line protocols. This review will firstly describe the initial development in monotherapy, considering then the different potential combination strategies which include both polichemotherapeutic regimens and less conventional approaches with new generation drugs. The potential use of Clofarabine as induction treatment for patients candidate to stem cell transplantation and within conditioning regimens will be finally evaluated
Rituximab maintenance or retreatment after autologous transplantation for relapsed follicular lymphoma?
No full text
The role of T-cells in the pathogenesis of myelodysplastic syndromes: Passengers and drivers
No full text
Reply to ‘Splenectomy status of the patient may have impact on response to donor lymphocyte infusions’ by Duygu Uckan-Çetinkaya et al.
No full textWe read with interest the recent letter to the editor by Uckan-Çetinkaya et al. concerning an article we have recently published in this journal. In this report, we investigated the factors affecting the dose required to achieve remission (effective cell dose (ECD)) in patients with chronic myeloid leukemia (CML) treated with donor lymphocyte infusions (DLI) in an escalating dose regimen (EDR), concluding that the response to DLI is dose dependent and that the main factors influencing the ECD are the disease stage at relapse and the degree of donor–recipient histocompatibility
The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS
No full textThe biological milieu and clinical picture of myelodysplastic syndromes (MDS) is characterised by a variety of immune mechanisms and manifestations, including an increased frequency of autoimmune disorders. The present review will try to shed some light on the potential clinical and pathogenetic implications of these immune processes in MDS by focusing on the beneficial effects exerted by some MDS-modifying therapies on autoimmune manifestations
- …
